Bristol Myers Squibb to Access Cellares’ Cell Therapy Manufacturing Platform in New $380 Million CAR-T Cell Therapy Deal

In a new agreement, Cellares will utilize its Cell Shuttle fully automated cell therapy manufacturing platform to manufacture select CAR-T cell therapies under development by Bristol Myers Squibb.